NovaShunt initiates study of its automated fluid removal implant
This article was originally published in Clinica
Executive Summary
Swiss firm NovaShunt has begun a pivotal clinical trial of its implanted automated fluid shunt (AFS) system in the treatment of ascites. Data from the trial will be used in NovaShunt's filing for European approval of the system.